Quest Partners LLC Lowers Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Quest Partners LLC reduced its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 42.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,072 shares of the biotechnology company’s stock after selling 17,928 shares during the quarter. Quest Partners LLC’s holdings in REGENXBIO were worth $253,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of RGNX. Assenagon Asset Management S.A. grew its stake in REGENXBIO by 258.7% during the second quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company’s stock valued at $9,552,000 after acquiring an additional 588,773 shares in the last quarter. Vanguard Group Inc. increased its stake in REGENXBIO by 9.8% in the 1st quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock worth $102,756,000 after acquiring an additional 436,043 shares during the last quarter. Artal Group S.A. purchased a new stake in shares of REGENXBIO during the 1st quarter worth approximately $5,268,000. Integral Health Asset Management LLC boosted its position in shares of REGENXBIO by 25.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock valued at $11,115,000 after acquiring an additional 190,000 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of REGENXBIO by 84.8% in the second quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company’s stock valued at $3,586,000 after purchasing an additional 140,666 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

Insider Activity

In related news, Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total transaction of $101,100.00. Following the sale, the director now owns 11,286 shares of the company’s stock, valued at $114,101.46. This trade represents a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 13.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on RGNX shares. Morgan Stanley reissued an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research note on Friday, November 15th. HC Wainwright dropped their target price on REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Raymond James reiterated an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a report on Thursday, October 10th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Finally, Chardan Capital reiterated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $35.27.

REGENXBIO Price Performance

Shares of REGENXBIO stock opened at $9.55 on Wednesday. The stock has a market cap of $473.15 million, a price-to-earnings ratio of -1.90 and a beta of 1.23. The firm’s 50-day moving average is $10.18 and its two-hundred day moving average is $11.96. REGENXBIO Inc. has a 1 year low of $8.53 and a 1 year high of $28.80.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.